Obesity pharmacotherapy: incretin action in the central nervous system
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Obesity pharmacotherapy: incretin action in the central nervous system
Authors
Keywords
-
Journal
TRENDS IN PHARMACOLOGICAL SCIENCES
Volume 44, Issue 1, Pages 50-63
Publisher
Elsevier BV
Online
2022-11-30
DOI
10.1016/j.tips.2022.11.001
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes
- (2022) Domenica M. Rubino et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes
- (2022) Dominik Dahl et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- A GLP‐1/glucagon (GCG)/CCK 2 receptors tri‐agonist provides new therapy for obesity and diabetes
- (2022) Songfeng Zhao et al. BRITISH JOURNAL OF PHARMACOLOGY
- Slow and Steady Wins the Race: 25 Years Developing the GLP-1 Receptor as an Effective Target for Weight Loss
- (2022) Nitya Kumar et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Structural determinants of dual incretin receptor agonism by tirzepatide
- (2022) Bingfa Sun et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Structural insights into multiplexed pharmacological actions of tirzepatide and peptide 20 at the GIP, GLP-1 or glucagon receptors
- (2022) Fenghui Zhao et al. Nature Communications
- A comparative transcriptomic analysis of glucagon-like peptide-1 receptor- and glucose-dependent insulinotropic polypeptide receptor-expressing cells in the hypothalamus
- (2022) Christopher Smith et al. APPETITE
- Tanycytes control hypothalamic liraglutide uptake and its anti-obesity actions
- (2022) Monica Imbernon et al. Cell Metabolism
- Tirzepatide Once Weekly for the Treatment of Obesity
- (2022) Ania M. Jastreboff et al. NEW ENGLAND JOURNAL OF MEDICINE
- A brainstem circuit for nausea suppression
- (2022) Chuchu Zhang et al. Cell Reports
- LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept
- (2022) Tamer Coskun et al. Cell Metabolism
- Tirzepatide induces a thermogenic-like amino acid signature in brown adipose tissue
- (2022) Ricardo J. Samms et al. Molecular Metabolism
- GIP receptor deletion in mice confers resistance to HFD-induced obesity via alterations in energy expenditure and adipose tissue lipid metabolism
- (2021) Geke Aline Boer et al. AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM
- The glucose-dependent insulinotropic polypeptide (GIP) regulates body weight and food intake via CNS-GIPR signaling
- (2021) Qian Zhang et al. Cell Metabolism
- The Role of Hypothalamic Inflammation in Diet-Induced Obesity and Its Association with Cognitive and Mood Disorders
- (2021) Sofia Dionysopoulou et al. Nutrients
- Glucagon-like peptide-1 (GLP-1) receptor activation dilates cerebral arterioles, increases cerebral blood flow, and mediates remote (pre)conditioning neuroprotection against ischaemic stroke
- (2021) Shereen Nizari et al. BASIC RESEARCH IN CARDIOLOGY
- A survey of the mouse hindbrain in the fed and fasted states using single-nucleus RNA sequencing
- (2021) Georgina K.C. Dowsett et al. Molecular Metabolism
- GIP Receptor Agonism Attenuates GLP-1 Receptor Agonist Induced Nausea and Emesis in Preclinical Models
- (2021) Tito Borner et al. DIABETES
- Effects of Cotadutide on Metabolic and Hepatic Parameters in Adults With Overweight or Obesity and Type 2 Diabetes: A 54-Week Randomized Phase 2b Study
- (2021) Rajaa Nahra et al. DIABETES CARE
- Gut peptide regulation of food intake – evidence for the modulation of hedonic feeding
- (2021) Orla R. M. Woodward et al. JOURNAL OF PHYSIOLOGY-LONDON
- Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial
- (2021) Julio Rosenstock et al. LANCET
- Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial
- (2021) Bernhard Ludvik et al. LANCET
- Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes
- (2021) Juan P. Frías et al. NEW ENGLAND JOURNAL OF MEDICINE
- Spatiotemporal GLP-1 and GIP receptor signaling and trafficking/recycling dynamics induced by selected receptor mono- and dual-agonists
- (2021) Aaron Novikoff et al. Molecular Metabolism
- Effects on weight loss and glycemic control with SAR441255, a potent unimolecular peptide GLP-1/GIP/GCG receptor triagonist
- (2021) Martin Bossart et al. Cell Metabolism
- Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial
- (2021) Stefano Del Prato et al. LANCET
- GLP-1 Suppresses Feeding Behaviors and Modulates Neuronal Electrophysiological Properties in Multiple Brain Regions
- (2021) Xin-Yi Chen et al. Frontiers in Molecular Neuroscience
- Anorectic and aversive effects of GLP-1 receptor agonism are mediated by brainstem cholecystokinin neurons, and modulated by GIP receptor activation
- (2021) Alessia Costa et al. Molecular Metabolism
- No Acute Effects of Exogenous Glucose-Dependent Insulinotropic Polypeptide on Energy Intake, Appetite, or Energy Expenditure When Added to Treatment With a Long-Acting Glucagon-Like Peptide 1 Receptor Agonist in Men With Type 2 Diabetes
- (2020) Natasha C. Bergmann et al. DIABETES CARE
- The early history of GIP 1969–2000: From enterogastrone to major metabolic hormone
- (2020) Vincent Marks PEPTIDES
- Gut Hormone GIP Induces Inflammation and Insulin Resistance in the Hypothalamus
- (2020) Yukiko Fu et al. ENDOCRINOLOGY
- How May GIP Enhance the Therapeutic Efficacy of GLP-1?
- (2020) Ricardo J. Samms et al. TRENDS IN ENDOCRINOLOGY AND METABOLISM
- Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist
- (2020) Francis S. Willard et al. JCI Insight
- Intestinal glucagon-like peptide-1 effects on food intake: Physiological relevance and emerging mechanisms
- (2020) Jean-Philippe Krieger PEPTIDES
- Chronic glucose-dependent insulinotropic polypeptide receptor (GIPR) agonism desensitizes adipocyte GIPR activity mimicking functional GIPR antagonism
- (2020) Elizabeth A. Killion et al. Nature Communications
- Area Postrema Cell Types that Mediate Nausea-Associated Behaviors
- (2020) Chuchu Zhang et al. NEURON
- Incretin Hormones and Type 2 Diabetes—Mechanistic Insights and Therapeutic Approaches
- (2020) Geke Aline Boer et al. Biology-Basel
- Effects of combined GIP and GLP-1 infusion on energy intake, appetite and energy expenditure in overweight/obese individuals: a randomised, crossover study
- (2019) Natasha C. Bergmann et al. DIABETOLOGIA
- Longer‐term liraglutide administration at the highest dose approved for obesity increases reward‐related orbitofrontal cortex activations to food cues: Implications for plateauing weight loss in response to anti‐obesity therapies
- (2019) Olivia M. Farr et al. DIABETES OBESITY & METABOLISM
- Glucose-Dependent Insulinotropic Polypeptide Receptor-Expressing Cells in the Hypothalamus Regulate Food Intake
- (2019) Alice E. Adriaenssens et al. Cell Metabolism
- Gut-derived GIP activates central Rap1 to impair neural leptin sensitivity during overnutrition
- (2019) Kentaro Kaneko et al. JOURNAL OF CLINICAL INVESTIGATION
- Glucagon-like peptide 1 (GLP-1)
- (2019) T.D. Müller et al. Molecular Metabolism
- Projected U.S. State-Level Prevalence of Adult Obesity and Severe Obesity
- (2019) Zachary J. Ward et al. NEW ENGLAND JOURNAL OF MEDICINE
- Molecular interactions of full-length and truncated GIP peptides with the GIP receptor – A comprehensive review
- (2019) Maria Buur Nordskov Gabe et al. PEPTIDES
- Liraglutide Modulates Appetite and Body Weight Through Glucagon-Like Peptide 1 Receptor–Expressing Glutamatergic Neurons
- (2018) Jessica M. Adams et al. DIABETES
- Semaglutide induces weight loss in subjects with type 2 diabetes regardless of baseline BMI or gastrointestinal adverse events in the SUSTAIN 1 to 5 trials
- (2018) Bo Ahrén et al. DIABETES OBESITY & METABOLISM
- Incretin hormones: Their role in health and disease
- (2018) Michael A. Nauck et al. DIABETES OBESITY & METABOLISM
- Progress and challenges in anti-obesity pharmacotherapy
- (2018) Daniel H Bessesen et al. Lancet Diabetes & Endocrinology
- Loss of dorsomedial hypothalamic GLP-1 signaling reduces BAT thermogenesis and increases adiposity
- (2018) Shin J. Lee et al. Molecular Metabolism
- Preproglucagon Neurons in the Nucleus of the Solitary Tract Are the Main Source of Brain GLP-1, Mediate Stress-Induced Hypophagia, and Limit Unusually Large Intakes of Food
- (2018) Marie K. Holt et al. DIABETES
- Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial
- (2018) Juan Pablo Frias et al. LANCET
- Association of BMI with overall and cause-specific mortality: a population-based cohort study of 3·6 million adults in the UK
- (2018) Krishnan Bhaskaran et al. Lancet Diabetes & Endocrinology
- LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept
- (2018) Tamer Coskun et al. Molecular Metabolism
- Occurrence of nausea, vomiting and diarrhoea reported as adverse events in clinical trials studying glucagon-like peptide-1 receptor agonists: A systematic analysis of published clinical trials
- (2016) Karolin Bettge et al. DIABETES OBESITY & METABOLISM
- Short-term administration of the GLP-1 analog liraglutide decreases circulating leptin and increases GIP levels and these changes are associated with alterations in CNS responses to food cues: A randomized, placebo-controlled, crossover study
- (2016) Olivia M. Farr et al. METABOLISM-CLINICAL AND EXPERIMENTAL
- Distribution and characterisation of Glucagon-like peptide-1 receptor expressing cells in the mouse brain
- (2015) Simon C. Cork et al. Molecular Metabolism
- Hypothalamic GLP-1: the control of BAT thermogenesis and browning of white fat
- (2015) Miguel López et al. Adipocyte
- GLP-1 Agonism Stimulates Brown Adipose Tissue Thermogenesis and Browning Through Hypothalamic AMPK
- (2014) D. Beiroa et al. DIABETES
- A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents
- (2014) Brian Finan et al. NATURE MEDICINE
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now